HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status
Wen‐Bin Ou(Brigham and Women's Hospital), Jonathan A. Fletcher(Brigham and Women's Hospital)
Cited by 37
Related Papers
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
|British Journal of Cancer|2019|165
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation
|Nature Communications|2017|69
Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives (Review)
|Oncology Letters|2018|55
YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways
|Oncogenesis|2021|35
Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53
|British Journal of Cancer|2016|33